ConvaTec steady in the health sector, shares track peer performance on the LSE

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 11:49.

ConvaTec (GB00BD3VFW73) ends the trading week as a defensive healthcare name on the London Stock Exchange, with investors focusing on how its shares compare to larger peers such as Smith & Nephew and Coloplast in wound management and ostomy care. The Friday lens is on sector performance and valuation spreads within European medical technology and healthcare supplies.

How ConvaTec fits into the peer group

ConvaTec is part of the UK-listed healthcare cohort alongside companies such as Smith & Nephew on the LSE and Denmark-based Coloplast on Nasdaq Copenhagen, all active in wound care and chronic care solutions. These peers typically show lower beta profiles compared to broader indices, reflecting their focus on recurring medical products and procedures.

Sector reports from outlets like MarketScreener highlight that European medical technology names generally trade at valuation premiums to the wider market, driven by steady demand and aging populations. ConvaTec's positioning in advanced wound dressings, ostomy care and continence management aligns it with these structural trends, even if it is smaller than some of its rivals.

Friday sector comparison and index context

On Fridays, many investors look at weekly relative performance between defensive healthcare shares such as ConvaTec and broader benchmarks like the FTSE 100 and STOXX Europe 600, which include larger pharmaceutical and medical device groups. Sector commentary from European market outlets notes that medical technology has recently traded broadly in line with main indices, with no pronounced rotation out of defensive healthcare.

ConvaTec's focus areas overlap partially with Smith & Nephew, which is active in wound care and orthopedics, and Coloplast, which is prominent in ostomy and continence care, making these two logical peers for performance and valuation comparison. Analyst and market data aggregators often group these companies in the same medical supplies and devices segment, helping investors benchmark margins and growth rates.

How ConvaTec makes its money

ConvaTec generates revenue primarily from advanced wound care, ostomy care, continence and critical care and infusion devices, targeting hospitals, clinics and home-care patients globally. Its portfolio includes modern wound dressings, ostomy pouches and catheters used in chronic disease management and post-surgical care.

Where the stock trades today

The ConvaTec shares (GB00BD3VFW73) trade on the London Stock Exchange in British pounds, with the latest verified price data available on UK quote services and sector platforms as of 2026-06-26, 11:30 BST.

This text is for informational purposes only and does not constitute investment advice, a recommendation or a solicitation to buy or sell securities. All data were obtained from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.